Evidence map›Paper›PMID 41954809›Full record

ArticleAIDS and behavior2026

What, how, and when matters: acceptability and preferences for HIV pre-exposure prophylaxis among people who inject drugs in New Delhi, India.

Allison M McFall, Aastha Kant, Jade Bell, Shobha Mohapatra, Rose P Kaptchuk, Aylur K Srikrishnan, Katie J C Zook, Shruti H Mehta, Steven J Clipman, Sunil S Solomon

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in AIDS and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Allison M McFallJohns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA. amcfall2@jhu.edu.ORCID http://orcid.org/0000-0002-1157-2931
Aastha KantSchool of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Jade BellSchool of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Shobha MohapatraYR Gaitonde Centre for AIDS Research and Education (YRGCARE), Chennai, India.
Rose P KaptchukJohns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
Aylur K SrikrishnanYR Gaitonde Centre for AIDS Research and Education (YRGCARE), Chennai, India.
Katie J C ZookSchool of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Shruti H MehtaJohns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
Steven J ClipmanSchool of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Sunil S SolomonSchool of Medicine, Johns Hopkins University, Baltimore, MD, USA.

Funding

Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Anna Palmer Durbin · 2012 to 2026
$67.0M
Individual, Network and Spatial Drivers of HIV and HCV among PWID in IndiaR01DA041736 · NIDA · JOHNS HOPKINS UNIVERSITY · PI SOLOMON, SUNIL SUHAS · 2016 to 2021
$5.0M
Long-Acting Injectables for Treatment of HIV among PWID (LIFT HIV)DP1DA060602 · NIDA · JOHNS HOPKINS UNIVERSITY · PI Sunil Suhas Solomon · 2024 to 2026
$3.0M
Molecular Networks and Deep Learning for Targeted HIV Interventions among PWIDDP2DA056130 · NIDA · JOHNS HOPKINS UNIVERSITY · PI CLIPMAN, STEVEN J. · 2022 to 2022
$2.5M
NIAID NIH HHS P30 AI094189NIDA NIH HHS DP1 DA060602NIDA NIH HHS DP2 DA056130NIDA NIH HHS R01 DA041736NIH HHS 1P30AI094189, R01DA041736, DP1DA060602
6 · The paper itself

Abstract

HIV pre-exposure prophylaxis (PrEP), particularly long-acting injectable formulations (LAI PrEP), has the potential to reduce the number of new infections among people who inject drugs (PWID), especially in low resource settings in the context of low coverage of harm reduction services, high HIV incidence, and substance use and instability. Few studies have examined PrEP perceptions, preferences, and service delivery models among these populations. We aimed to characterize acceptability, perceptions, preferences, and barriers/facilitators of different PrEP options, including LAI PrEP, among a cohort of PWID in New Delhi, India. This mixed methods study (March 2024-March 2025) included focus group discussions (FGDs) followed by cross-sectional survey data covering PrEP awareness, acceptability, and preferences and a discrete choice experiment (DCE) on LAI PrEP. FGDs indicated there was little prior awareness of and interest in PrEP, with concerns about what PrEP medications may do to their body or how it would make them feel. Hesitation surrounding PrEP was also driven by low personal HIV risk perception. Among 389 surveyed, 96% had no prior knowledge of PrEP; 72% indicated they would rather not take PrEP, with 20% preferring LAI PrEP, 5% weekly pills, 3% undecided, and no one preferred daily pills. Preferred characteristics of LAI PrEP were less frequent injections, delivery at existing healthcare clinics, and payment or incentives. PrEP programs of any modality aiming to build demand and deliver PrEP to PWID should consider how these populations often differ substantively in knowledge, needs, and preferences from other populations that have so far been the focus of PrEP campaigns.

Indexed as

acceptabilityIndialong-acting injectable pre-exposure prophylaxisoral pre-exposure prophylaxispeople who inject drugspre-exposure prophylaxis/PrEPpreferences

Identifiers

PMID41954809
PMCPMC13169917

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.